Lobbying client

TRI-SOURCE PHARMA

Pharmaceutical manufacturer/distributor in both human and animal health care industries.

Filings
11
Filed by
1
Reported in-house
—
Reported by firms
$190,000

Reported lobbying by year

The larger of in-house and firm-reported each year, $ thousands 2018 to 2020

Filings

11 filings, newest first.
Filing Filed by Amount
1st Quarter - Termination (No Activity)
1st Quarter 2020
MERCURY STRATEGIES, LLC — reported
4th Quarter - Report (No Activity)
4th Quarter 2019
MERCURY STRATEGIES, LLC — reported
3rd Quarter - Report (No Activity)
3rd Quarter 2019
MERCURY STRATEGIES, LLC — reported
2nd Quarter - Amendment (No Activity)
2nd Quarter 2019
MERCURY STRATEGIES, LLC — reported
2nd Quarter - Report (No Activity)replaced
2nd Quarter 2019
MERCURY STRATEGIES, LLC — reported
1st Quarter - Report (No Activity)
1st Quarter 2019
MERCURY STRATEGIES, LLC — reported
4th Quarter - Report
4th Quarter 2018
MERCURY STRATEGIES, LLC $50,000 reported
3rd Quarter - Report
3rd Quarter 2018
MERCURY STRATEGIES, LLC $50,000 reported
2nd Quarter - Report
2nd Quarter 2018
MERCURY STRATEGIES, LLC $60,000 reported
1st Quarter - Report
1st Quarter 2018
MERCURY STRATEGIES, LLC $30,000 reported

Filed by

Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.

FirmReportsAmount
MERCURY STRATEGIES, LLC 9 $190,000

Issues lobbied

How many report sections named each issue, counting the current version of each report.

IssueCodeMentions
Health Issues HCR 5

From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.